AKT1 and neoplasm: This increased sensitivity to allosteric AKT inhibitors suggests that this class of drugs may be able to target, at least partly, non-catalytic AKT functions and could, therefore, represent a better therapeutic option in some tumours with constitutively increased AKT-dependent signalling due to abnormally high cellular levels of PIP3 or PI(3,4)P2 caused by PI3K-pathway-activating mutations.